Nanoformulations for Combination or Cascade Anticancer Therapy

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2017 Jun 19

PMID 28624477

Citations 42

Authors

Lei Miao

Shutao Guo

C Michael Lin

Qi Liu

Leaf Huang

Affiliations

Soon will be listed here.

Abstract

Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.

Citing Articles

Advances in understanding ferroptosis mechanisms and their impact on immune cell regulation and tumour immunotherapy.

Zhu Z, Wu X, Zhang J, Zhu M, Tian M, Zhao P Discov Oncol. 2025; 16(1):153.

PMID: 39930297 PMC: 11811334. DOI: 10.1007/s12672-025-01911-x.

Classification of Nanomaterial Drug Delivery Systems for Inflammatory Bowel Disease.

Wang H, Zhou F, Shen M, Ma R, Yu Q Int J Nanomedicine. 2025; 20:1383-1399.

PMID: 39925683 PMC: 11804237. DOI: 10.2147/IJN.S502546.

Bilosomes and Niosomes for Enhanced Intestinal Absorption and In Vivo Efficacy of Cytarabine in Treatment of Acute Myeloid Leukemia.

Said A, Arafa M, El-Dakroury W, Alshehri S, El Maghraby G Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770414 PMC: 11677554. DOI: 10.3390/ph17121572.

Therapeutic Efficacy of Quercetin and Its Nanoformulation Both the Mono- or Combination Therapies in the Management of Cancer: An Update with Molecular Mechanisms.

Eity T, Bhuia M, Chowdhury R, Ahmmed S, Sheikh S, Akter R J Trop Med. 2024; 2024:5594462.

PMID: 39380577 PMC: 11461079. DOI: 10.1155/2024/5594462.

Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy.

Sun L, Li Z, Lan J, Wu Y, Zhang T, Ding Y Front Pharmacol. 2024; 15:1389922.

PMID: 38831883 PMC: 11144913. DOI: 10.3389/fphar.2024.1389922.

References

Guo S, Lin C, Xu Z, Miao L, Wang Y, Huang L . Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano. 2014; 8(5):4996-5009. PMC: 4046782. DOI: 10.1021/nn5010815. View

Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

Conde J, Oliva N, Zhang Y, Artzi N . Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat Mater. 2016; 15(10):1128-38. PMC: 6594055. DOI: 10.1038/nmat4707. View

Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

Hernandez-Gil J, Cobaleda-Siles M, Zabaleta A, Salassa L, Calvo J, Mareque-Rivas J . An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects. Adv Healthc Mater. 2015; 4(7):1034-42. DOI: 10.1002/adhm.201500080. View

Brown E, McKee T, DiTomaso E, Pluen A, Seed B, Boucher Y . Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9(6):796-800. DOI: 10.1038/nm879. View

Liao L, Liu J, Dreaden E, Morton S, Shopsowitz K, Hammond P . A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecin. J Am Chem Soc. 2014; 136(16):5896-9. PMC: 4105175. DOI: 10.1021/ja502011g. View

Lima R, Martins L, Guimaraes J, Sambade C, Vasconcelos M . Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells. Cancer Gene Ther. 2004; 11(5):309-16. DOI: 10.1038/sj.cgt.7700706. View

Bauer B, Hartz A, Fricker G, Miller D . Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol. 2004; 66(3):413-9. DOI: 10.1124/mol.66.3.. View

10.

Masuyama H, Nakatsukasa H, Takamoto N, Hiramatsu Y . Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol Pharmacol. 2007; 72(4):1045-53. DOI: 10.1124/mol.107.037937. View

11.

Xiao H, Song H, Yang Q, Cai H, Qi R, Yan L . A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance. Biomaterials. 2012; 33(27):6507-19. DOI: 10.1016/j.biomaterials.2012.05.049. View

12.

Feldman E, Lancet J, Kolitz J, Ritchie E, Roboz G, List A . First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011; 29(8):979-85. PMC: 4520927. DOI: 10.1200/JCO.2010.30.5961. View

13.

Ding Y, Su S, Zhang R, Shao L, Zhang Y, Wang B . Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures. Biomaterials. 2016; 113:243-252. DOI: 10.1016/j.biomaterials.2016.10.053. View

14.

Vong L, Nagasaki Y . Combination Treatment of Murine Colon Cancer with Doxorubicin and Redox Nanoparticles. Mol Pharm. 2015; 13(2):449-55. DOI: 10.1021/acs.molpharmaceut.5b00676. View

15.

Wilson K, de Jong S, Kazem M, Lall R, Hope M, Cullis P . The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine. J Gene Med. 2008; 11(1):14-25. DOI: 10.1002/jgm.1267. View

16.

Chavanpatil M, Patil Y, Panyam J . Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm. 2006; 320(1-2):150-6. DOI: 10.1016/j.ijpharm.2006.03.045. View

17.

Stylianopoulos T, Jain R . Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A. 2013; 110(46):18632-7. PMC: 3832007. DOI: 10.1073/pnas.1318415110. View

18.

Hermeking H . The miR-34 family in cancer and apoptosis. Cell Death Differ. 2009; 17(2):193-9. DOI: 10.1038/cdd.2009.56. View

19.

Schrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S . Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology. 2011; 53(4):1192-205. PMC: 3076070. DOI: 10.1002/hep.24108. View

20.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View